Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Angiogenesis Modulating Agents (Phase 2)
Anus Neoplasms (Phase 2)
Bevacizumab (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Chemoradiotherapy (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Death (Phase 1)
DNA Mismatch Repair (Phase 2)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 3)
Endometrial Neoplasms (Phase 1)
Epstein-Barr Virus Infections (Early Phase 1)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 4)
General Surgery (Phase 3)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hypopharyngeal Neoplasms (Phase 2)
Immune Checkpoint Inhibitors (Phase 2)
Immunotherapy (Phase 2/Phase 3)
Induction Chemotherapy (Phase 1)
Kidney Neoplasms (Phase 2)
Laryngeal Neoplasms (Phase 2)
Liposarcoma (Phase 1/Phase 2)
Liver Neoplasms (Phase 3)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, T-Cell (Phase 3)
Melanoma (Phase 3)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 1)
Mouth Neoplasms (Phase 1)
Nasopharyngeal Carcinoma (Phase 3)
Nasopharyngeal Diseases (Phase 2)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neuroendocrine Tumors (Phase 3)
Oocytes (Phase 2)
Oxaliplatin (Phase 2)
Pancreatic Neoplasms (Phase 2)
Penile Neoplasms (Phase 2)
Perioperative Period (Phase 2)
Radiotherapy (Phase 3)
Rectal Neoplasms (Phase 2)
Rituximab (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2/Phase 3)
Stomach Neoplasms (Phase 3)
Survival (Phase 2/Phase 3)
Thoracic Neoplasms (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Tracheal Neoplasms (Phase 2)
Transplants (Early Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urologic Neoplasms (Phase 1)
Uterine Cervical Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue